Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
1
Radiation-induced Myofibroblasts Promote Tumor Growth via Mitochondrial
ROS-activated TGFβ Signaling
Tsutomu Shimura1*
, Megumi Sasatani2, Hidehiko Kawai
2, Kenji Kamiya
2, Junya
Kobayashi3, Kenshi Komatsu
3, Naoki Kunugita
1
1 Department of Environmental Health, National Institute of Public Health 2-3-6
Minami, Wako, Saitama, Japan 351-0197
2 Department of Experimental Oncology, Research Center for Radiation Genome
Medicine, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima
University, Hiroshima, Japan 734-8553
3 Department of Genome Dynamics, Radiation Biology Center, Kyoto University;
Kyoto, Japan 606-8501
Running title: TGFβ Pathway-mediated Acquisition of Myofibroblasts
Keywords: myofibroblast, mitochondria, ROS, TGF- signaling, tumor
microenvironment
Financial support: This research was supported by a grant from the JSPS KAKENHI
Grant Number 18H03377, 17K19944, Industrial Disease Clinical Research Grants from
the Japanese Ministry of Health, Labour, and Welfare and in part by NIFS Collaborative
Research Program (NIFS13KOBA028).
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
2
*Corresponding author: Tsutomu Shimura, PhD
Department of Environmental Health, National Institute of Public Health, 2-3-6 Minami,
Wako, Saitama 351-0197, Japan
Tel. +81-48-458-6261; Fax +81-48-458-6270; Email: [email protected]
Disclosure of Potential Conflict of interests
The authors declare no competing financial interests.
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
3
Abstract
Fibroblasts are a key stromal cell in the tumor microenvironment (TME) and promote
tumor growth via release of various growth factors. Stromal fibroblasts in cancer, called
cancer-associated fibroblasts (CAFs), are related to myofibroblasts, an activated form of
fibroblast. While investigating the role of stroma fibroblasts on radiation-related
carcinogenesis, it was observed following long-term fractionated radiation (FR) that the
morphology of human diploid fibroblasts changed from smaller spindle shapes to larger
flat shapes. These cells expressed smooth muscle actin (α-SMA) and platelet-derived
growth factor receptors (PDGFRs), markers of myofibroblasts and CAFs, respectively.
Long-term FR induces progressive damage to the fibroblast nucleus and mitochondria
via increases in mitochondrial reactive oxygen species (ROS) levels. Here it is
demonstrated that long-term FR-induced α-SMA positive cells have decreased
mitochondrial membrane potential and activated oxidative stress responses. Antioxidant
N-acetyl cysteine suppressed radiation-induced mitochondrial damage and generation of
myofibroblasts. These results indicate that mitochondrial ROS are associated with the
acquisition of myofibroblasts after long-term FR. Mechanistically, mitochondrial ROS
activated TGFβ signaling which in turn mediated the expression of α-SMA in
radiation-induced myofibroblasts. Finally, in vivo tumor growth analysis in a human
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
4
tumor xenograft model system revealed that long-term FR-induced myofibroblasts
promote tumor growth by enhancing angiogenesis.
Implications: Radiation affects malignant cancer cells directly and indirectly via
molecular alterations in stromal fibroblasts such as activation of TGFβ and angiogenic
signaling pathways.
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
5
Introduction
Ionizing radiation offers numerous clinical benefits for diagnosis and therapy.
Radiotherapy (RT) is one of the most widely used therapies for cancer treatment. In
patients being treated with RT, the radiation dose is limited by the tolerance of healthy
tissue. To preserve normal tissue function, treatment is delivered in multiple small
fractions of radiation (fractionated radiation; FR) with dose of around 2 Gy for 5 to 7
weeks (1). Technological advances have significantly improved clinical outcomes of RT
by enabling increased radiation doses directed very specifically at a tumor. However,
the late effects of cancer treatment such as radiation-induced second malignancies are a
serious public health issue (1).
Ionizing radiation is a carcinogen that causes leukemia and solid cancers in humans.
Cancer risk following exposure to radiation was estimated in a life span study of atomic
bomb survivors from Hiroshima and Nagasaki (2,3). This epidemiological research
showed an increased in leukemia and solid cancer risk among atomic bomb survivors.
DNA double-strand breaks are a major cause of the detrimental biological effects of
radiation. DNA mutations associated with radiation-related carcinogenesis, the so-called
“radiation signature,” have been intensively investigated to elucidate the risk of
radiation-induced cancer (4,5). Currently, radiation signatures remain a matter of debate
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
6
in a variety of cancers because the development of cancer is a multistep process that
occurs over long periods of time. Basic research on radiation-related carcinogenesis is
indispensable for obtaining a rigorous body of scientific evidence on the estimated risk
of cancer following ionizing radiation.
Mitochondria govern many cellular metabolic processes and are the energy power
house in healthy cells (6,7). Ionizing radiation damages mitochondria and impairs
mitochondrial respiration, leading to the overproduction of mitochondrial reactive
oxygen species (ROS). Mitochondria are the sites of intracellular ROS generation
through mitochondrial oxidative phosphorylation (OXPHOS) and are more vulnerable
to ROS toxicity than the nucleus (8,9). We recently discovered that long-term
FR-induced enhanced mitochondrial activity is evident by elevated mitochondrial
membrane potential and elevated activity of mitochondrial complex IV (cytochrome c
oxidase), which fills the energy demands for the chronic DNA damage response in
irradiated human fibroblasts (8,9). Subsequent reduction of the intercellular antioxidant
glutathione (GSH) via continuous activation of mitochondrial oxidative phosphorylation
(OXPHOS) causes oxidative stress and genomic instability in irradiated cells.
Mitochondrial dysfunction may be critical in facilitating radiation-related
carcinogenesis. Tumor cells preferentially metabolize glucose into lactate through
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
7
glycolysis than using mitochondrial oxidative phosphorylation for energy production
because of their inability to respire (10). Aerobic glycolysis is a metabolic hallmark of
cancer, known as the Warburg effect (11,12). Metabolic alterations associated with
mitochondrial dysfunction increase tumorigenesis. Thus, cancer metabolism is strongly
related to cancer development and resistance to anti-cancer medication and radiation
(13,14). To control the quality of mitochondria, the parkin E3 ubiquitin ligase is
recruited to abnormal mitochondria with low membrane potential (ΔΨm) and promotes
their clearance by selective degradation (mitophagy) (15,16). ATM loss leads to
defective mitophagy and increased frequency of abnormal mitochondria with decreased
mitochondrial membrane potential. ATM-deficient cells showed highly radiosensitive
phenotypes when subjected to low-dose long-term FR, which induced in these cells
severe mitochondrial damage, as assessed by mitochondrial fragmentation, and cell
death proved to occur through mitochondria-mediated apoptosis (17). Furthermore, we
previously reported that mitochondrial radiation responses such as increase in
mitochondrial biogenesis and OXPHOS were not observed after low-dose, long-term
FR in ATM-deficient cells in contrast to ATM-complemented cells. ATM-dependent
signaling pathways have an essential role in the crosstalk between the nucleus and
mitochondria in irradiated cells (8,17).
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
8
Fibroblasts are cells in connective tissue that contribute to the synthesis and deposition
of extracellular matrix (ECM) to induce changes in the tissue microenvironment. The
tumor microenvironment plays an important role in tumor initiation, progression, and
metastasis (18-20). Cancer-associated fibroblasts (CAFs), which are related to
myofibroblasts, are an activated from of fibroblasts in tumor tissues, are distinguishable
from their normal counterparts, and promote tumor growth by inducing angiogenesis
and recruiting bone marrow-derived endothelial progenitor cells (21). Expression of
α-SMA characterizes fibroblast-to-myofibroblast differentiation (22). CAF produce a
variety of growth factors, chemokines, and matrix-degrading proteases to promote
tumor growth and cancer cell aggressiveness, such as tumor angiogenesis, extracellular
matrix remodeling, tumor proliferation, invasion, and metastasis (18-20). CAF-derived
stromal-cell-derived factor 1 (SDF1) regulates the proliferation of breast cancer cells
(23). CAF modulates extracellular matrix (ECM) remodeling ability via producing
ECM-degrading proteases such as the MMPs and collagen (24,25). CAF also interacts
with the microvasculature by secreting VEGF (26). However, the role of tumor
microenvironments in radiation-induced carcinogenesis is not well understood.
We here investigated the association between mitochondrial oxidative stress and the
formation of tumor microenvironments during the development of radiation-related
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
9
tumors. We examined whether ionizing radiation promotes myofibroblast differentiation
to facilitate tumor growth.
Materials and Methods
Cell culture conditions and drugs
Normal human diploid lung fibroblasts (MRC-5 and TIG-3) were purchased from the
Health Science Research Resources Bank and grown in minimum essential medium
(Nacalai Tesque, Kyoto, Japan) supplemented with 10% heat-inactivated fetal calf
serum. HeLa, a cervical cancer cell line, was obtained from the Cell Resource Center
for Biomedical Research, IDAC, Tohoku University. The cells were grown in
RPMI1640 medium (Nacalai Tesque, Kyoto, Japan) supplemented with 5%
heat-inactivated fetal calf serum. LY361949 and NAC were purchased from Sigma (San
Diego, CA, USA). NAC was continuously added to the media at a final concentration of
1 mM during exposure to long-term FR. Media was changed at 2- or 3-day intervals.
Cells were treated with LY361949 (3 µM) for 1 week during FR exposure (from 25 to
31 days).
Irradiation experiments
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
10
Cells were irradiated using a 150-kVp X-ray generator (Model MBR-1505R2, Hitachi)
with 0.5-mm Cu and 0.1-mm Al filters. We previously reported that human fibroblasts
no longer proliferate under FR exposure for 31 days when cells were exposed to ≥0.5
Gy of X-rays per fraction. In contrast, cells exposed to 0.01 or 0.05 Gy FR continue to
grow exponentially for 31 day (27). Therefore, X-ray fractions (0.01 or 0.05 Gy) were
administered twice a day for 5 days/week in this study. The total doses delivered over
31 days were 0.46 and 2.3 Gy for cells exposed to FR of 0.01 and 0.05 Gy, respectively.
Cells continued to grow for 31 days following exposure to 0.01 or 0.05 Gy FR. When
cells reached 80% confluency, they were subcultured in a new flask.
Immunofluorescence
Immunofluorescence staining was performed as previously described (27,28). Cells
were seeded onto 18 × 18-mm cover slips, which were placed in 35-mm tissue culture
dishes and cultured overnight. The cells on cover slips were fixed with 4%
formaldehyde for 10 min and permeabilized with 0.5% Triton X-100 for 5 min. For
double staining with -SMA (Sigma) and parkin, cells were fixed with 4%
formaldehyde at 37˚C for 15 min and permeabilized with 0.2% Triton X-100 for 10 min.
Antibodies against -SMA (Sigma), parkin (Santa Cruz Biotechnology, Santa Cruz, CA,
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
11
USA), PDGF (Abcam), Nrf2 (Nichirei Bioscience, Tokyo, Japan), Phospho-TGF-
receptor serine 165 (Thermo Fisher), and secondary antibodies conjugated with Alexa
Fluor 488 (Molecular Probes, Eugene, OR, USA) or Cy-3 (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) were used. Cells were counterstained for DNA
with Hoechst 33258 (4 µg/mL in Vectashield mounting medium; Vector Laboratories,
Burlingame, CA, USA). Images were captured using a CCD camera attached to a
fluorescence microscope (Keyence). For each data point, we counted more than 50 cells
from at least three independent samples.
Measurement of TGF-β, bFGF, and VEGF
TGF-β, bFGF, and VEGF were measured using an assay kit (Sigma) according to the
manufacturer’s instructions. The activity was reported as units/mg of cell extract.
Animal experiments
The study design was approved by the Animal Ethical Committee of the National
Institute of Public Health. Male BALB/c nu/nu mice at 5 weeks of age were used. All
mice were maintained in our animal facility on a 12-h light/dark cycle at a controlled
temperature (23˚C ± 2˚C). For transplantation, 5 × 106 HeLa cells and 1.5 × 10
7 normal
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
12
fibroblasts cells in 100 l of saline were injected in the dorsal area of mice. Tumor size
was measured with calipers. The tumor volume (V) was estimated by V = 0.5×(length ×
width2). We calculated the average of tumor size for each data point from at least three
mouse.
Immunohistochemistry
Tumor tissues were fixed in 10% buffered formalin. Immunohistochemistry staining
was performed as previously described (29). Image acquisition and evaluation were
conducted with a Keyence BZ-X700 fluorescence microscope with the Hybrid Cell
Count software (BZ-II Analyzer, Keyence, Osaka, Japan). Three or four images were
used for the image analysis in each slide. We calculated the a-SMA positive area ratio in
HeLa tumors or in small intestine of Apc Min/+ mouse from at least two independent
samples.
Statistical analysis
Error bars represent standard deviations. All experiments were repeated at least three
times using independent samples. Following one-way ANOVA, the Dunnett test was
used to detect significant differences among the means of three or more independent
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
13
groups. Student’s t-test was used for the tumor growth analysis. Double and single
asterisks indicate significant differences with p-values of <0.01 and <0.05, respectively.
Results
Myofibroblast induction by long-term FR
We investigated the effect of exposure to FR for 31 days (long-term FR) in human lung
fibroblasts, TIG-3, and MRC-5. Fibroblasts are elongated and spindle-shaped.
Following long-term FR, there are pronounced differences in the morphology of some
irradiated fibroblasts, which appear flat with a leaf-like shape. Cells with altered
morphology expressed a myofibroblast marker, α smooth muscle actin (α-SMA) (Figure
1A). Approximately 20% of TIG-3 and MRC-5 cells exposed to long-term FR were
positive for -SMA staining (Figure 1A, right panel). Cells exposed to <5 Gy acute
single radiation (SR) did not induce -SMA expression, although -SMA-positive cells
appeared after exposure to 10 Gy SR (Supplemental Figure 1). The platelet-derived
growth factor receptor (PDGFR) is expressed in CAFs (30,31). Immunofluorescent
staining (Figure 1B) or FACS analysis using a phycoerythrin (PE)-conjugated
anti-PDGFR antibody (PE-140a) (Figure 1C) showed an increased number of
PDGFR-expressing cells after long-term FR. According to the previous reports, only a
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
14
small fraction of cells is co-expressed with PDGFR and alpha-SMA (21). We previously
reported that long-term FR of TIG-3 and MRC-5 cells induced mitochondrial oxidative
stress via decreased glutathione (GSH) levels and the accumulation of mitochondrial
ROS (8,9). This can be mitigated by the antioxidant N-acetyl-cysteine (NAC), a GSH
precursor, which increases intracellular GSH levels. We therefore examined the role of
mitochondrial oxidative stress on long-term FR-induced acquisition of myofibroblasts.
Statistical comparisons revealed that treatment of long-term FR cells with NAC
suppressed the induction of -SMA or PDGFR in TIG-3 and MRC-5 cells (Figure 1A,
1B, and 1C).
Mitochondrial stress in myofibroblast
To clarify the association between myofibroblast differentiation and mitochondrial
dysfunction, we examined -SMA-positive myofibroblasts for mitochondrial oxidative
damage. Cells were immunostained with antibodies specific for the E3 ubiquitin ligase,
parkin, which recognizes damaged mitochondria with low ΔΨm. Myofibroblasts
positive for -SMA had parkin foci in the mitochondria of cells exposed to long-term
FR (Figure 2A). The number of single and double positive for each marker, and total
cells was shown in the table. We observed a statistically significant increase in the
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
15
number of TIG-3 and MRC-5 cells double-positive for -SMA and parkin foci
following long-term FR compared with non-irradiated cells (Figure 2A, right graph).
We previously reported that mitochondrial damage is attributable to increased
mitochondrial ROS levels in cells exposed to long-term FR (8). We therefore examined
the activation of the oxidative stress response in long-term FR-induced myofibroblasts.
The transcription factor Nrf2 relocates from the cytoplasm to the nucleus upon
activation and regulates the expression of oxidative stress-inducible genes that defend
against oxidative stress (32). In cells exposed to long-term FR, -SMA-positive
myofibroblasts showed the nuclear accumulation of Nrf2 (Figure 2B). We further
investigated the mechanism of Nrf2 regulation following long-term FR. NAC treatment
suppressed nuclear accumulation of Nrf2 in -SMA-positive myofibroblasts (Figure
2B). These results indicated that mitochondrial oxidative stress was likely to be induced
in myofibroblasts after long-term FR.
TGF- activation in myofibroblast
In healthy tissue, ionizing radiation induces the expression of TGF- as part of the
damage recovery mechanism (33). TGF- signaling plays a key role in
fibroblast-to-myofibroblast differentiation by inducing the expression of -SMA (22).
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
16
To determine the role of TGF- signaling in long-term FR-induced acquisition of
myofibroblasts, we measured the concentration of secreted TGF- in the culture
medium of long-term FR cells (Figure 3A). TGF-levels were significantly increased
by long-term FR compared with non-irradiated cells. NAC eliminated the increased
TGF- concentration in long-term FR cells (Figure 3A). TGF- binds to its type 2
receptor (TGFR2), which then phosphorylates the type 1 receptor (TGFR1). The active
receptor complex phosphorylates Smad2/Smad3 (34). Elevated levels of phosphorylated
TGFR1 following long-term FR in MRC-5 cells indicated that the TGF- signaling
pathway was activated (Figure 3B). We used an inhibitor of TGF- signaling,
LY-364947, to test the role of TGF-signaling and NAC in long-term FR-induced
myofibroblast differentiation. Treatment with LY-364947 prevented TGF- signaling
following long-term FR. Similarly, NAC suppressed long-term FR-induced activation of
TGF- signaling (Figure 3B). The phosphorylation of TGFR1 was detected in
-SMA-positive myofibroblasts (Figure 3C). Treatment with LY-364947 abrogated
long-term FR-induced myofibroblast differentiation by the inhibition of the TGF-
signaling pathway (Figure 3B, 3C right panel, 3D).
Long-term FR cells enhance in vivo tumor growth
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
17
To test the in vivo interaction between cancer cells and long-term FR-induced
myofibroblasts, we made a human tumor xenograft of HeLa cells, HeLa +
non-irradiated fibroblasts (HeLa + 0FR), HeLa + long-term FR fibroblasts (HeLa +
0.05FR), HeLa + NAC-treated fibroblasts (HeLa + NAC 0FR), and HeLa +
NAC-treated long-term FR fibroblasts (HeLa + NAC 0.05FR) in a 3:1 ratio in nude
mice. Individual tumor measurements data for each mouse at each time point were
shown in supplemental figure 2. We determined the average slope of tumor growth
curves for each tumor type. HeLa cells with long-term FR irradiated fibroblasts
generated tumors of greater volume than HeLa cells with non-irradiated fibroblasts
(Figure 4A). HeLa + NAC 0FR and HeLa + NAC 0.05FR tumors did not show a growth
advantage in nude mice compared with HeLa + 0FR tumors (Figure 4B).
Immunohistochemistry with an anti--SMA antibody showed that HeLa + 0.05FR
tumors comprised a higher number of -SMA-positive myofibroblasts than HeLa and
HeLa + 0FR tumors (Figure 5A). The adenomatous polyposis coli (Apc) Min/+ mouse
model is widely used to investigate the radiation-induced formation of intestinal
adenoma. Using anti--SMA antibodies, we observed that radiation-induced tumors had
many -SMA-positive fibroblasts surrounding tumor cells (Figure 5B). Quantification
data of -SMA positive area ratio in HeLa tumors or in small intestine of Apc Min/+
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
18
mouse were shown in Figure 5C.
Myofibroblasts promote angiogenesis
To characterize long-term FR-induced myofibroblasts, we measured levels of
extracellular factor released from long-term FR cells. Compared with non-irradiated
control cells, levels of basic fibroblast growth factor (bFGF) and vascular endothelial
growth factor (VEGF) were higher in the culture medium of long-term FR cells (Figure
6A, 6B). Treatment with NAC eliminated the stimulation of bFGF and VEGF in
long-term FR cells.
We examined in vivo tumor angiogenesis in human tumor xenografts. CD31+
endothelial progenitor cells proportion was increased in tumor xenografts containing
long-term FR cells compared with those containing non-irradiated fibroblasts (Figure
6C).
Discussion
We investigated the harmful effects of long-term FR exposure in relation to medical
exposure in normal cells. Our data demonstrated that long-term FR-induced
myofibroblasts that express α-SMA and PDGFR have an abnormal, flat, large
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
19
morphology. For FR, a total radiation dose of 0.46 Gy (0.01 Gy/fractions, twice a day, 5
days/week for 31days) is sufficient to induce the acquisition of myofibroblasts.
However, a radiation dose of 10 Gy is required to induce -SMA-expressing
myofibroblasts in acute SR. Thus, the acquisition of myofibroblasts is influenced by the
dose and method of radiation exposure. The induction of myofibroblasts following
long-term FR is associated with mitochondrial dysfunction and oxidative stress, as
shown by the formation of parkin foci and nuclear accumulation of Nrf2 in
-SMA-expressing cells, respectively. We recently showed that long-term FR exposure
elevates mitochondrial OXPHOS in response to the persistent energy requirement of the
DNA damage response (8). The activation of mitochondrial OXPHOS leads to the
continuous mitochondrial ROS generation and a decrease in antioxidant GSH levels
(35). Alterations in GSH levels are not observed following SR (9). Long-term FR, but
not SR, causes mitochondrial oxidative stress in human fibroblasts by perturbing
mitochondrial redox. Treatment with antioxidant NAC restored GSH levels and
decreased radiation-induced mitochondrial ROS levels (9). NAC suppressed
myofibroblast appearance after long-term FR. We provided the first demonstration that
persistent mitochondrial oxidative stress induced by long-term FR stimulates the
differentiation of myofibroblasts from normal fibroblasts.
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
20
Myofibroblasts are an activated form of fibroblasts that play important roles in wound
healing (36). TGF- signaling is a master switch for radiation-induced fibrosis (37).
Plasma TGF- levels can be used to predict the risk of radiation-induced lung injury.
TGF- plays an essential role in ECM remodeling, cell mobility, and immune function
modulation. TGF- regulates the formation and breakdown of connective tissue (34,37).
We demonstrated that long-term FR stimulates TGF-signaling in irradiated cells via
mitochondrial ROS-mediated activation of fibroblasts by TGF--signaling (Figure 7).
We showed that ROS are involved in the activation of TGF-. The pro-TGF-complex
is a large molecule containing TGF- and the latency association protein (LAP). ROS
directly oxidizes LAP and indirectly activates MMP2, which in turn cleaves LAP to
release active TGF-. TGF- then suppresses the expression of several
antioxidant enzymes including glutaredoxin, catalase, superoxide dismutase, and
glutathione peroxidase and decreases the concentration of GSH (39). Receptor
stimulation for TGF- results in the activation of a signaling pathway that increases the
transcription of the gene encoding smooth muscle actin to induce myofibroblast
differentiation. Consequently, mitochondria-mediated oxidative stress is associated with
the induction of TGF-signaling.
During skin would healing, recruited fibroblasts and differentiated myofibroblasts
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
21
proliferate and deposit ECM to form granulation tissue (36). Myofibroblasts are
responsible for excessive ECM production, leading to fibrosis (22). Therefore, at the
later stages of wound healing, myofibroblasts are driven into senescence to control
fibrogenesis. These senescent cells promote tissue remodeling and clearance of
myofibroblasts (40). Cellular senescence is a potent tumor-suppressive mechanism to
prevent malignant transformation by arresting the growth of abnormal cells. Senescent
fibroblasts release senescence-associated secretory phenotype factors, including
interleukins, chemokines, growth factors, secreted protease, and ECM components, that
modify the tissue microenvironment (41,42). Therefore, cellular senescence is both
beneficial and deleterious for tumorigenesis.
We demonstrated that -SMA-expressing fibroblasts existed within tumors in small
intestine of Apc Min/+ mouse induced by ionizing radiation. Alterations in fibroblasts
play a key role in tumor bed effects on radiation-related tumorigenesis (19,20). Stromal
fibroblasts stimulate tumorigenesis by releasing factors that act on tumor cell growth.
Our data showed that long-term FR-induced myofibroblasts release bFGF and TGF-
which are key mediators of fibroblast activation. This study contains a limitation of not
using fibroblasts and tumor cells of similar histology, because we used lung-derived
fibroblasts with a cervical cancer cell line. In vivo animal experiments showed that
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
22
long-term FR-induced myofibroblasts promote tumor growth of HeLa cells in nude
mice. Tumor progression is clearly dependent on angiogenesis. Long-term FR-induced
VEGF appears to play a major role in angiogenesis in tumor tissues.
In conclusion, long-term FR-induced mitochondrial stress causes the acquisition of
activated fibroblasts (myofibroblasts). Radiation-induced myofibroblasts promote tumor
growth in vivo. Alterations in stromal cells can contribute to radiation-related tumors.
Radiation affects malignant cancer cells directly and indirectly via the tumor stroma.
Author Contributions
Conception and design: T. Shimura
Development of methodology: T. Shimura
Acquisition of data (provided animals, acquired and managed patients,
provided facilities, etc.): M. Sasatani, H. Kawai, J. Kobayashi, K. Komatsu
Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
computational analysis): T. Shimura
Writing, review, and/or revision of the manuscript: T. Shimura, M. Sasatani,
H. Kawai, J. Kobayashi
Administrative, technical, or material support (i.e., reporting or organizing
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
23
data, constructing databases): M. Sasatani, H. Kawai, J. Kobayashi, K. Komatsu, K.
Kamiya
Study supervision: N. Kunugita
Acknowledgments
We thank Dr. Shinkai Youichi for the measurement of TGF-β. This research was
supported by a grant from the JSPS KAKENHI Grant Number 18H03377, 17K19944,
Industrial Disease Clinical Research Grants from the Japanese Ministry of Health,
Labour, and Welfare and in part by NIFS Collaborative Research Program
(NIFS13KOBA028). This work was performed at the Joint Usage/Research Center
(Radiation Biology Center), Kyoto University, and the Program of the network-type
joint Usage/Research Center for Radiation Disaster Medical Science of Hiroshima
University, Nagasaki University, and Fukushima Medical University.
References
1. Bhatti P, Veiga LHS, Ronckers CM, Sigurdson AJ, Stovall M, Smith SA, et al. Risk of
Second Primary Thyroid Cancer after Radiotherapy for a Childhood Cancer in a
Large Cohort Study: An Update from the Childhood Cancer Survivor Study.
Radiation research 2010;174:741-52
2. Hsu WL, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K, et al. The
Incidence of Leukemia, Lymphoma and Multiple Myeloma among Atomic Bomb
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
24
Survivors: 1950-2001. Radiation research 2013;179:361-82
3. Ozasa K, Shimizu Y, Suyama A, Kasagi F, Soda M, Grant EJ, et al. Studies of the
mortality of atomic bomb survivors, Report 14, 1950-2003: an overview of cancer and
noncancer diseases. Radiation research 2012;177:229-43
4. Hamatani K, Eguchi H, Ito R, Mukai M, Takahashi K, Taga M, et al. RET/PTC
rearrangements preferentially occurred in papillary thyroid cancer among atomic
bomb survivors exposed to high radiation dose. Cancer Res 2008;68:7176-82
5. Harada H, Harada Y, Kimura A. Implications of somatic mutations in the
AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular
therapeutic directions for MDS. Current cancer drug targets 2006;6:553-65
6. Kowaltowski AJ, de Souza-Pinto NC, Castilho RF, Vercesi AE. Mitochondria and
reactive oxygen species. Free radical biology & medicine 2009;47:333-43
7. Figueira TR, Barros MH, Camargo AA, Castilho RF, Ferreira JC, Kowaltowski AJ,
et al. Mitochondria as a source of reactive oxygen and nitrogen species: from
molecular mechanisms to human health. Antioxidants & redox signaling
2013;18:2029-74
8. Shimura T, Sasatani M, Kawai H, Kamiya K, Kobayashi J, Komatsu K, et al.
ATM-mediated mitochondrial damage response triggered by nuclear DNA damage in
normal human lung fibroblasts. Cell Cycle 2017
9. Shimura T, Sasatani M, Kamiya K, Kawai H, Inaba Y, Kunugita N. Mitochondrial
reactive oxygen species perturb AKT/cyclin D1 cell cycle signaling via oxidative
inactivation of PP2A in lowdose irradiated human fibroblasts. Oncotarget
2016;7:3559-70
10. Chen Q, Cai ZJ, Mao PX, Zhai YM, Mitchell PB, Tang YL. Effects of risperidone on
glucose metabolism in Chinese patients with schizophrenia: a prospective study.
Journal of psychiatric research 2008;43:124-8
11. Warburg O. On the origin of cancer cells. Science 1956;123:309-14
12. Warburg O, Wind F, Negelein E. The Metabolism of Tumors in the Body. The Journal
of general physiology 1927;8:519-30
13. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell
2008;134:703-7
14. Munoz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives
and future directions. Cell death & disease 2012;3:e248
15. Tolkovsky AM. Mitophagy. Biochimica et biophysica acta 2009;1793:1508-15
16. Kubli DA, Gustafsson AB. Mitochondria and Mitophagy The Yin and Yang of Cell
Death Control. Circ Res 2012;111:1208-21
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
25
17. Shimura T, Kobayashi J, Komatsu K, Kunugita N. Severe mitochondrial damage
associated with low-dose radiation sensitivity in ATM- and NBS1-deficient cells. Cell
Cycle 2016;15:1099-107
18. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer
2016;16:582-98
19. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401
20. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu
Rev Pathol-Mech 2006;1:119-50
21. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-Associated Fibroblasts Are
Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in
an NF-kappa B-Dependent Manner (vol 17, pg 135, 2010). Cancer Cell 2010;17:523-
22. Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest
Dermatol 2007;127:526-37
23. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al.
Stromal fibroblasts present in invasive human breast carcinomas promote tumor
growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell
2005;121:335-48
24. Boire A, Covic L, Agarwal A, Jacques S, Sherifl S, Kuliopulos A. PAR1 is a matrix
metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast
cancer cells. Cell 2005;120:303-13
25. Pankova D, Chen YL, Terajima M, Schliekelman MJ, Baird BN, Fahrenholtz M, et al.
Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor
Stroma. Mol Cancer Res 2016;14:287-95
26. Fukumura D, Xavier R, Sugiura T, Chen Y, Park EC, Lu NF, et al. Tumor induction
of VEGF promoter activity in stromal cells. Cell 1998;94:715-25
27. Shimura T, Hamada N, Sasatani M, Kamiya K, Kunugita N. Nuclear accumulation
of cyclin D1 following long-term fractionated exposures to low-dose ionizing
radiation in normal human diploid cells. Cell Cycle 2014;13:1248-55
28. Shimura T, Toyoshima M, Adiga SK, Kunoh T, Nagai H, Shimizu N, et al.
Suppression of replication fork progression in low-dose-specic p53-dependent
S-phase DNA damage checkpoint. Oncogene 2006;25:5921-32
29. Toda Y, Kono K, Abiru H, Kokuryo K, Endo M, Yaegashi H, et al. Application of
tyramide signal amplification system to immunohistochemistry: A potent method to
localize antigens that are not detectable by ordinary method. Pathol Int
1999;49:479-83
30. Micke P, Ostman A. Tumour-stroma interaction: cancer-associated fibroblasts as
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
26
novel targets in anti-cancer therapy? Lung Cancer-J Iaslc 2004;45:S163-S75
31. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling
in the proangiogenic tumor stroma revealed by pharmacological targeting. Plos Med
2008;5:123-38
32. Ma Q. Role of Nrf2 in Oxidative Stress and Toxicity. Annu Rev Pharmacol
2013;53:401-+
33. Martin M, Vozenin MC, Gault N, Crechet F, Pfarr CM, Lefaix JL. Coactivation of
AP-1 activity and TGF-beta 1 gene expression in the stress response of normal skin
cells to ionizing radiation. Oncogene 1997;15:981-9
34. Pohlers D, Brenmoehl J, Loffler I, Muller CK, Leipner C, Schultze-Mosgau S, et al.
TGF-beta and fibrosis in different organs - molecular pathway imprints. Bba-Mol
Basis Dis 2009;1792:746-56
35. Shimura T, Kunugita N. Mitochondrial reactive oxygen species-mediated genomic
instability in low-dose irradiated human cells through nuclear retention of cyclin D1.
Cell Cycle 2016;15:1410-4
36. Diegelmann RF, Evans MC. Wound healing: An overview of acute, fibrotic and
delayed healing. Front Biosci 2004;9:283-9
37. Anscher MS. Targeting the TGF-beta 1 Pathway to Prevent Normal Tissue Injury
After Cancer Therapy. Oncologist 2010;15:350-9
38. Andarawewa KL, Paupert J, Pal A, Barcellos-Hoff MH. New rationales for using
TGF beta inhibitors in radiotherapy. Int J Radiat Biol 2007;83:803-11
39. Liu RM, Pravia KAG. Oxidative stress and glutathione in TGF-beta-mediated
fibrogenesis. Free Radical Bio Med 2010;48:1-15
40. Jun JI, Lau LF. Cellular senescence controls fibrosis in wound healing. Aging-Us
2010;2:627-31
41. Freund A, Orjalo AV, Desprez PY, Campisi J. Inflammatory networks during cellular
senescence: causes and consequences. Trends Mol Med 2010;16:238-46
42. Coppe JP, Desprez PY, Krtolica A, Campisi J. The Senescence-Associated Secretory
Phenotype: The Dark Side of Tumor Suppression. Annu Rev Pathol-Mech
2010;5:99-118
Figure Legends
Figure 1. Induction of -SMA and PDGFR expression by long-term FR.
(A) Images of -SMA staining in non-irradiated control cells (0FR) and TIG-3
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
27
cells exposed to 0.01 FR for 31 days (0.01FR) with/without NAC treatment. Cells were
stained 24 h after the last FR. Scale bar = 50 µm. The percentage of TIG-3 and MRC-5
cells with -SMA staining for each irradiation method is shown in the graph on the right.
The total number of cells observed in this analysis was shown in table. (B) Images of
PDGFR staining in 0FR cells and 0.01FR cells of TIG-3. The percentage of TIG-3 and
MRC-5 cells with PDGFR staining for each irradiation method is shown in the graph on
the right. The total number of cells observed in this analysis was shown in table. (C)
FACS analysis for PDGFR (PE-140a) in non-irradiated control (0FR; dotted black lines)
and indicated cells (solid lines) in TIG-3 cells. The percentage of TIG-3 and MRC-5
cells with PDGFR staining for each irradiation method are shown in the graph on the
right.
Figure 2. Mitochondrial dysfunction and oxidative damage in long-term FR-induced
myofibroblasts.
(A) Images of -SMA and parkin staining and (B) Images of -SMA and Nrf2 staining
in 0FR and 0.05FR cells of TIG-3. Scale bar = 50 µm. The number of single and double
positive for each marker, and total cells was shown in the table (percentage in
parenthesis). For each data point, more than 50 cells were counted from at least four
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
28
independent samples. The percentage of double-positive TIG-3 and MRC-5 cells for
each irradiation method was shown in the graph on the right.
Figure 3. Activation of TGF- signaling for myofibroblast differentiation.
(A) TGF- levels in TIG-3 and MRC-5 cells 72 h after the last FR. We calculated the
average of TGF-levels for each data point from at least five independent samples.
Asterisks indicate a significant difference in the levels of TGF- in irradiated cells
compared with non-irradiated cells. (B) Western blots for Phospho-TGFR1, TGFR1,
and actin in 0FR and 31FR cells with/without NAC or LY364947 treatment. (C) Images
of -SMA and phospho-TGFR1 staining in 0FR and 0.05FR cells of TIG-3 cells. Scale
bar = 50 µm. Cells were stained 24 h after the last FR. The number of single and double
positive for each marker, and total cells was shown in the table (percentage in
parenthesis). For each data point, more than 50 cells were counted from at least three
independent samples. (D) Western blots for -SMA and actin in 0FR and 31FR cells
with/without NAC or LY364947 treatment.
Figure 4. The role of radiation-induced myofibroblast for in vivo tumor growth
(A) In vivo tumor growth of HeLa cells, HeLa + non-irradiated fibroblasts (HeLa +
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
29
0FR), HeLa + long-term FR fibroblasts (HeLa + 0.05FR). (B) In vivo tumor growth of
HeLa cells, HeLa + NAC-treated fibroblasts (HeLa + NAC 0FR), and HeLa +
NAC-treated long-term FR fibroblasts (HeLa + NAC 0.05FR). We calculated the
average of tumor size for each data point from at least three independent samples. Black
and red asterisks indicate the significance change of tumor volume in HeLa +
non-irradiated fibroblasts samples with/without NAC treatment compared to that of
HeLa cells and HeLa + long-term FR fibroblasts samples with/without NAC treatment
compared to that of HeLa cells, respectively.
Figure 5. Expression of -SMA in human tumor xenografts and Apc Min/+ mice.
(A) Histological sections of human tumor xenografts on day 31 were immunostained
with -SMA, hematoxylin, and eosin. Scale bar = 100 µm. (B) Immunostaining with
-SMA, hematoxylin, and eosin in histological sections of intestinal tumors from Apc
Min/+ mice. Scale bar = 100 µm. Magnified images for -SMA staining were inserted.
(C) Quantification data of immunostaining with -SMA in HeLa tumors and in small
intestine of Apc Min/+ mouse.
Figure 6. The role of long-term FR-induced myofibroblasts in angiogenesis.
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
30
Levels of bFGF (A) and VEGF (B) in TIG-3 and MRC-5 cells 72 h after the last FR.
Asterisks indicate significant differences in the amount of bFGF or VEGF in irradiated
cells compared with non-irradiated cells. We calculated the average of the amount of
bFGF or VEGF for each data point from at least four independent samples. (C)
Quantification of blood vessel density in HeLa tumors. Blood vessels in five fields of
three tumors were quantified. Image of cd31 staining in HeLa + non-irradiated
fibroblasts (HeLa + 0FR) and HeLa + long-term FR fibroblasts (HeLa + 0.05FR). DNA
was stained with Hoechst. Scale bar = 100 µm.
Figure 7. Schematic representation of mitochondrial ROS-mediated myoblast
differentiation via TGF--signaling.
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321
Published OnlineFirst July 24, 2018.Mol Cancer Res Tsutomu Shimura, Megumi Sasatani, Hidehiko Kawai, et al.
SignalingβMitochondrial ROS-activated TGFRadiation-induced Myofibroblasts Promote Tumor Growth via
Updated version
10.1158/1541-7786.MCR-18-0321doi:
Access the most recent version of this article at:
Material
Supplementary
http://mcr.aacrjournals.org/content/suppl/2018/07/24/1541-7786.MCR-18-0321.DC1
Access the most recent supplemental material at:
Manuscript
Authorbeen edited. Author manuscripts have been peer reviewed and accepted for publication but have not yet
E-mail alerts related to this article or journal.Sign up to receive free email-alerts
Subscriptions
Reprints and
To order reprints of this article or to subscribe to the journal, contact the AACR Publications
Permissions
Rightslink site. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC)
.http://mcr.aacrjournals.org/content/early/2018/07/24/1541-7786.MCR-18-0321To request permission to re-use all or part of this article, use this link
on April 8, 2021. © 2018 American Association for Cancer Research. mcr.aacrjournals.org Downloaded from
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on July 24, 2018; DOI: 10.1158/1541-7786.MCR-18-0321